Methadone, alternatively called Dolophine, functions as a synthetic opioid utilized in treating opioid dependence and chronic pain conditions. Developed during the late 1930s in Germany and approved for U.S. use in 1947, methadone became the preferred medication for opioid detoxification and maintenance therapy. The drug operates similarly to morphine by functioning as a mu-opioid receptor antagonist, mimicking endogenous opioids and influencing multiple neurotransmitters including acetylcholine, norepinephrine, substance P, and dopamine. Additionally, methadone demonstrates strong N-methyl-D-aspartate (NMDA) receptor antagonism. Within the racemic mixture of R and S enantiomers, the R-form delivers most analgesic effects, exhibiting approximately ten times greater affinity for mu and delta receptors compared to the S-form, with a binding profile resembling morphine except for reduced kappa receptor affinity.
Methadone administration occurs through oral or parenteral routes, with a primary application being maintenance therapy for heroin-dependent individuals. This substitution allows patients to avoid withdrawal symptoms and heroin cravings while reducing associated health risks. The medication also treats chronic pain conditions; however, its shorter analgesic duration of 4-6 hours relative to half-life necessitates more frequent dosing at lower amounts. Surgically, methadone significantly reduces postoperative analgesic needs compared to shorter-acting opioids. Higher dosages yield extended half-lives favorable for clinical effects, with major surgeries requiring 20 mg doses while moderate procedures require approximately 10 mg. Rapid central nervous system equilibration via intravenous administration produces prompt analgesia, typically requiring only a single induction dose.
Long-term methadone use produces numerous side effects including "sweating, constipation, disturbance of appetite leading to weight gain, sexual dysfunction, sedation, insomnia, and hypoventilation." Severe consequences involve apnea, respiratory failure, hypoxia, and potential coma or death, predominantly from elevated dosages. Respiratory depression represents a significant concern requiring careful monitoring due to central opioid receptor activity. Toxicity develops from incorrect dosing frequency, as the extended half-life promotes drug accumulation. Concurrent medications affecting liver enzymatic metabolism and binge alcohol consumption can compromise methadone effectiveness and increase respiratory depression risk. Gradual tapering not exceeding 1 mg daily minimizes withdrawal symptoms, with symptomatic treatments addressing remaining withdrawal effects.